Ultra-wealthy invest record amounts in longevity biotech
Global investment in longevity biotechnology reached a record $18.4 billion in 2025, driven by high-net-worth individuals and family offices seeking both personal health benefits and financial returns. Prominent investors such as Jeff Bezos, Sam Altman, and Peter Thiel have backed various startups in the space, including Altos Labs, Retro Biosciences, and multiple other longevity-focused ventures. The trend is fueled by younger wealthy generations interested in enhancing their appearance, fitness levels, and overall vitality. The industry now emphasizes 'healthspan'—the period of life spent in good health—rather than simply extending lifespan. This shift has led to increased demand for products like peptides, supplements, IV drips, red-light therapies, and biomarker trackers. According to Longevity.Technology CEO Phil Newman, the surge is not speculative but driven by scientific progress. A Bank of America survey also shows that nearly all wealthy investors are taking steps to optimize their health and consider longevity a key part of wealth planning.
Tickers: $BAC
Topics: biotechnology investments longevity wealth management